NCIC Clinical Trials Group
Closed portfolio snapshot
According to ClinicalTrials.gov-derived indexes, NCIC Clinical Trials Group sits in the top decile of US sponsors by registered trial count (#714 of 15,742 sponsors by registered trial count).
NCIC Clinical Trials Group: 21 sponsored US clinical trials, none currently recruiting.
NCIC Clinical Trials Group sponsors 21 registered US clinical trials on ClinicalTrials.gov, none currently recruiting, and 21 completed. 9 of these trials are in Phase 3-4 (later-stage) and 9 in Phase 1-2 (earlier-stage). The most-studied condition in this pipeline is Breast Cancer, with 2 trials.
Top-decile sponsor footprint
NCIC Clinical Trials Group ranks in the top decile of sponsors by registered trial count (#714 of 15,742 sponsors by registered trial count). Volume at this scale usually reflects a long institutional pipeline, read phase tilt and therapeutic areas below before treating it as current-year activity.
Trial completion reliability score
21 of 21 decided trials (Completed vs. Terminated on ClinicalTrials.gov) reached their planned completion (100.0%), vs. national p10 68.4% / p90 100% among 1,234 sponsors with at least 10 decided trials. Still-open trials (Recruiting, Active-not-recruiting, Not-yet-recruiting) are excluded since they have not reached an outcome yet.
Indexed trials (enrollment closed)
21 total, page 1 of 1
Phase II Study of Interleukin-21 (rIL-21) vs Dacarbazine (DTIC) in Patients With Metastatic or Recurrent Melanoma
NCT01152788
PF-00299804 in Stage IIIB or Stage IV Non-Small Cell Lung Cancer Not Responding to Standard Therapy for Advanced or Metastatic Cancer
NCT01000025
Bone Mineral Density in Postmenopausal Women at Increased Risk of Breast Cancer And Who Are Receiving Exemestane on MAP3
NCT00688246
Docetaxel and Prednisone With/Out OGX-011 in Recurrent or Metastatic Prostate Cancer That Did Not Respond to Previous Hormone Therapy
NCT00258388
Exemestane in Preventing Cancer in Postmenopausal Women at Increased Risk of Developing Breast Cancer
NCT00083174
Chemotherapy Before Autologous Stem Cell Transplantation +/- Rituximab in Relapsed or Refractory Aggressive Non-Hodgkin's Lymphoma
NCT00078949
Bortezomib in Treating Patients With Waldenstrom's Macroglobulinemia
NCT00045695
Gemcitabine With/Out Erlotinib in Unresectable Locally Advanced/Metastatic Pancreatic Cancer
NCT00026338
Exemestane in Reducing Breast Density in Postmenopausal Women at Risk for Breast Cancer
NCT00066586
Letrozole in Preventing Breast Cancer in Postmenopausal Women Who Are at Increased Risk for Breast Cancer Due to High Breast Density
NCT00238316
Combination Chemotherapy With or Without Colony-stimulating Factors in Treating Women With Breast Cancer
NCT00014222
Thalidomide and Prednisone Following Peripheral Stem Cell Transplantation in Treating Patients With Multiple Myeloma
NCT00006890
Flavopiridol in Treating Patients With Recurrent, Locally Advanced, or Metastatic Soft Tissue Sarcoma
NCT00005974
Paclitaxel + Carboplatin With/ut BMS-275291 in Advanced or Metastatic Non-small Cell Lung Cancer
NCT00006229
MG98 in Treating Patients With Advanced Solid Tumors
NCT00003890
ISIS 5132 in Treating Patients With Metastatic or Recurrent Ovarian Cancer
NCT00003892
Tamoxifen With or Without Octreotide in Treating Postmenopausal Women With Stage I, Stage II, or Stage III Breast Cancer
NCT00002864
Radiation or Observation Only in Endometrial Cancer Who Have Undergone Surgery
NCT00002807
Combination Chemotherapy in Treating Patients With Multiple Myeloma
NCT00002678
Immediate Compared With Delayed Chemotherapy in Advanced Colorectal Cancer Without Signs or Symptoms of Disease
NCT00002570
Vinorelbine + Cisplatin or No Further Therapy in Non-small Cell Lung Cancer That Has Been Surgically Removed
NCT00002583
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 1 | 1 |
| Phase 2 | 8 |
| Phase 3 | 9 |
Therapeutic Areas
How the NCIC Clinical Trials Group archive is shaped
21 indexed studies, none listed as recruiting (0% open); 21 completed (100%).
Phase mix: 9 late (III/IV) vs 9 early (I/II) (balanced across stages).
Top condition: Breast Cancer (2 trials), 2 others listed.
How to read a closed sponsor archive
When recruiting_count is zero, the indexed set is completed or otherwise not open. Phase tilt still describes where archived studies sat on the investigational pathway. Re-check ClinicalTrials.gov before acting.
NCIC Clinical Trials Group: archived-pipeline peers nationwide
Peers matched on 21 indexed studies with no current recruiting: volume and archive shape, not condition overlap.
NCIC Clinical Trials Group sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together.
Sponsors near 21 archived trials
- AEterna Zentaris · 21 trials · 0% recruiting
- Amphastar Pharmaceuticals · 21 trials · 5% recruiting
- Apellis Pharmaceuticals · 21 trials · 10% recruiting
- Array Biopharma, now a wholly owned subsidiary of Pfizer · 21 trials · 0% recruiting
Sponsors with similar archive density (± trial count)
- 10xBio · 0% recruiting · 3 trials
- 22nd Century Group · 0% recruiting · 3 trials
- 23andMe · 0% recruiting · 6 trials
- 3-C Institute for Social Development · 0% recruiting · 14 trials
Related
What to do with this NCIC Clinical Trials Group page
21 registered trials is a research-attention snapshot, not an endorsement of NCIC Clinical Trials Group or any single study.
- None of NCIC Clinical Trials Group's trials are currently recruiting in this registry; that can change as new trials post, or check the broader research index. Browse research indexes
- Breast Cancer is the condition NCIC Clinical Trials Group studies most, compare against other sponsors active in the same condition before evaluating a specific study. See Breast Cancer trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
NCIC Clinical Trials Group pipeline card: 21 registered trials from official public datasets.Report a data error.